Home/Pipeline/ANORO ELLIPTA

ANORO ELLIPTA

Chronic Obstructive Pulmonary Disease (COPD)

Approved/CommercialMarketed

Key Facts

Indication

Chronic Obstructive Pulmonary Disease (COPD)

Phase

Approved/Commercial

Status

Marketed

Company

Innoviva

About Innoviva

Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.

View full company profile

Therapeutic Areas

Respiratory Infectious Disease Oncology

Other Chronic Obstructive Pulmonary Disease (COPD) Drugs

Drug	Company	Phase	Status
Verekitug	Upstream Bio	Phase 2	Ongoing
FHD-909	Fulcrum Therapeutics	Preclinical	Discovery
PUR0200	Pulmatrix	Formulation Development	Legacy Program